Dimensional Fund Advisors LP Trims Stock Holdings in Krystal Biotech, Inc. (NASDAQ:KRYS)

Dimensional Fund Advisors LP cut its position in shares of Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 1.9% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 588,599 shares of the company's stock after selling 11,662 shares during the quarter. Dimensional Fund Advisors LP owned about 2.05% of Krystal Biotech worth $92,214,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Wilmington Savings Fund Society FSB purchased a new position in Krystal Biotech during the 3rd quarter valued at about $40,000. Covestor Ltd lifted its holdings in shares of Krystal Biotech by 972.7% during the fourth quarter. Covestor Ltd now owns 708 shares of the company's stock valued at $111,000 after purchasing an additional 642 shares during the last quarter. Avanza Fonder AB purchased a new position in shares of Krystal Biotech during the fourth quarter valued at approximately $119,000. KBC Group NV boosted its position in shares of Krystal Biotech by 46.3% in the 4th quarter. KBC Group NV now owns 939 shares of the company's stock worth $147,000 after purchasing an additional 297 shares in the last quarter. Finally, Blue Trust Inc. grew its stake in shares of Krystal Biotech by 74.4% in the 4th quarter. Blue Trust Inc. now owns 1,015 shares of the company's stock worth $159,000 after buying an additional 433 shares during the last quarter. 86.29% of the stock is owned by hedge funds and other institutional investors.

Krystal Biotech Stock Up 0.3 %

KRYS traded up $0.47 during midday trading on Friday, hitting $166.16. 228,173 shares of the company traded hands, compared to its average volume of 294,547. The company's 50-day moving average is $174.92 and its 200 day moving average is $171.22. The firm has a market capitalization of $4.80 billion, a PE ratio of 55.57 and a beta of 0.79. Krystal Biotech, Inc. has a 52 week low of $141.72 and a 52 week high of $219.34.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last issued its quarterly earnings data on Monday, February 24th. The company reported $1.52 earnings per share for the quarter, beating analysts' consensus estimates of $1.29 by $0.23. Krystal Biotech had a net margin of 30.69% and a return on equity of 11.41%. The company had revenue of $91.10 million for the quarter, compared to the consensus estimate of $91.35 million. During the same quarter in the prior year, the firm earned $0.30 earnings per share. The firm's revenue for the quarter was up 116.4% compared to the same quarter last year. On average, sell-side analysts predict that Krystal Biotech, Inc. will post 6.14 earnings per share for the current fiscal year.

Insider Activity

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $177.79, for a total value of $4,444,750.00. Following the transaction, the insider now owns 1,463,711 shares of the company's stock, valued at approximately $260,233,178.69. This represents a 1.68 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CAO Kathryn Romano sold 750 shares of the firm's stock in a transaction dated Thursday, February 27th. The stock was sold at an average price of $175.22, for a total value of $131,415.00. Following the completion of the transaction, the chief accounting officer now directly owns 12,604 shares in the company, valued at $2,208,472.88. The trade was a 5.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 13.70% of the company's stock.

Analyst Ratings Changes

KRYS has been the subject of a number of recent research reports. Citigroup lifted their price objective on Krystal Biotech from $206.00 to $215.00 and gave the company a "neutral" rating in a research note on Thursday, February 20th. Chardan Capital lifted their price target on Krystal Biotech from $212.00 to $218.00 and gave the stock a "buy" rating in a research report on Thursday, February 20th. Cantor Fitzgerald reissued an "overweight" rating and set a $215.00 price objective on shares of Krystal Biotech in a research report on Thursday, February 20th. Jefferies Financial Group assumed coverage on shares of Krystal Biotech in a report on Wednesday, March 5th. They issued a "buy" rating and a $245.00 target price for the company. Finally, HC Wainwright increased their price target on shares of Krystal Biotech from $221.00 to $240.00 and gave the company a "buy" rating in a report on Monday, April 28th. One equities research analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Buy" and an average price target of $222.71.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).